Global Growth Hormone Study in Adults With Prader-Willi Syndrome
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to measure the effect of growth hormone treatment on
physical and psychosocial health in adults of 30 years or older with Prader-Willi syndrome.
Patients are randomized to placebo or growth hormone treatment during the first year. They
will switch treatment during the second year, so that each participant receives one year of
growth hormone treatment and one year of placebo (cross-over study). We hypothesize that
growth hormone treatment will improve the physical and psychosocial health.
Phase:
Phase 3
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
Foundation for Prader-Willi Research Pfizer Prader-Willi Fonds